Evidence map›Paper›PMID 36533358›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2022

[Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome].

X Y Xing, J X Zhang, F Y Zhu, Y F Wang, X Y Zhou, Y H Li

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

X Y XingDepartment of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China.
J X ZhangDepartment of Internal Medicine, Beijing Prison Administration Qinghe Branch, Tianjin 300481, China.
F Y ZhuDepartment of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China.
Y F WangDepartment of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China.
X Y ZhouDepartment of Rheumatology and Immunology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China.
Y H LiDepartment of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China.
Peking University · CNBeijing Administration Institute · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the clinical and immunological features of dermatomyositis (DM) complicated with macrophage activation syndrome (MAS). The demographic and clinical characteristics of five patients diagnosed with DM complicated with MAS hospitalized in the Department of Rheumatology and Immunology, Peking University People ' s Hospital from 2011 to 2021 were collected. The results of clinical manifestations, laboratory tests, immunological features, treatments and prognosis were analyzed and summarized. In this study, five female patients in Peking University People's Hospital with an average age of 63.8 (44.0-83.0) years and an average disease duration of 16.1 (1.5-48.0) months. All the patients had typical DM rash (such as heliotrope sign, V/shawl sign or Gottron's sign/papules). They all had muscle involvement (including myalgia or muscle weakness). Two patients had positive myositis-specific antibodies (MSAs), in which case 1 had anti-TIF1-γ antibody and case 5 had anti-NXP-2 antibody. Four patients had interstitial lung disease except case 3. All of the cases developed MAS in the active stage of DM. Common manifestations of MAS in these five patients included high-grade fever, cytopenia, decreased fibrinogen, elevated ferritin and increased soluble CD25. Case 1 presented with neutropenia (0.6×10

Indexed as

AfibrinogenemiaDermatomyositisHypertriglyceridemiaMacrophage Activation SyndromeNeutropeniaThrombocytopeniaAutoantibodiesFemaleFerritinsFibrinogenHumansMiddle AgedAutoantibodiesFerritinsFibrinogenDermatomyositisInfectionMacrophage activation syndromeMyositis specific autoantibodiesPrognosis

Identifiers

PMID36533358
PMCPMC9761815
OpenAlexW4312065889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.